Supplementary Information

Title:

Molecularly Self-Fueled Nano-Penetrator for Nonpharmaceutical Treatment of Thrombosis and Ischemic Stroke

Authors: Hongyuan Zhang^{1#}, Zhiqiang Zhao^{1#}, Shengnan Sun¹, Sen Zhang², Yuequan Wang¹, Xuanbo Zhang¹, Jin Sun¹, Zhonggui He¹, Shenwu Zhang^{1*}, Cong Luo^{1*}

Affiliations:

¹Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical

University, Shenyang 110016, P. R. China

²Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education,

Shenyang Pharmaceutical University, Shenyang 110016, P. R. China

*Corresponding authors:

Cong Luo, Ph.D. and Shenwu Zhang, Ph.D.

Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical

University, No. 103 Wenhua Road, Shenyang 110016, P. R. China

E-mail: luocong@syphu.edu.cn; zhangshenwu@aliyun.com

[#]These authors contributed equally to this work.



Supplementary Fig. 1 Synthesis route of BNN6.



Supplementary Fig. 2 (**a**) Mass spectrometry result of BNN6. (**b**) H NMR spectra of BNN6(400 MHz, CDCl3) δ7.50 (4H), 5.05-4.89 (2H), 2.00-1.84 (2H), 1.71-1.49 (2H), 1.25 (t, J =7.6 Hz, 6H), 1.08 (td, J = 7.4, 5.3 Hz, 6H). (**c**) 13C NMR spectra of BNN6 (400 MHz, CDCl3) δ128.03, 124.95, 52.05, 28.31, 17.40, 10.07.



Supplementary Fig. 3 Aqueous dispersion of BNN6.



Supplementary Fig. 4 Long-term stability of (**a**) B-BD NAs, (**b**)T-BD NAs, and (**c**)N-BD NAs stored at 4°C under dark conditions.



Supplementary Fig. 5 (a) Representative In vitro thrombus-targeting fluorescence images (scale bar = 100 μ m) and (b) quantitative results in artificial whole blood clots treated with different formulations Data are presented as mean ± SD (n=3 independent experiments) Source data are provided as a Source Data file. One-way ANOVA (one-sided) with Dunnett's multiple comparisons test was used for the analysis of data and adjusted P value.



Supplementary Fig. 6 Concentration-absorbance calibration curve of NaNO₂ determined by the Griess assay at 540 nm.



Supplementary Fig. 7 NO generation from T-BD NAs at different concentrations of BNN6 under 808 nm laser irradiation (2W/cm²), Data are presented as mean \pm SD (n=3 independent experiments) Source data are provided as a Source Data file.



Supplementary Fig. 8 NO generation from T-BD NAs (0.548 mg/mL of DiR and 0.452 mg/mL of BNN6) with different laser power density (808 nm), Data are presented as mean ± SD (n=3 independent experiments) Source data are provided as a Source Data file.



Supplementary Fig. 9 Particle size of PLGA-BD NPs.



Supplementary Fig. 10 Photothermal curves of T-BD NAs and PLGA-BD NPs under 808 nm laser irradiation (2W/cm²), Data are presented as mean \pm SD (n=3 independent experiments) Source data are provided as a Source Data file.



Supplementary Fig. 11 Movement trajectories of T-BD NAs recorded by a fluorescence microscope with Nikon camera under 808 nm laser irradiation with different power intensity from 0 W/cm² to 2 W/cm², scale bar = 1 μ m. Experiment was repeated three times independently with similar results.



Supplementary Fig. 12 Motion speed of T-BD NAs in PBS (pH 7.4) under 808 nm laser irradiation with different power intensity from 0 W/cm² to 2 W/cm², Data are presented as mean \pm SD (n=3 independent experiments) Source data are provided as a Source Data file.



Supplementary Fig. 13 (a) Movement trajectories and (b) motion speed of T-BD NAs in PBS (pH 7.4) containing 10% FBS under 808 nm laser irradiation (2 W/cm², 60 s), scale bar = 1 μ m. Data are presented as mean \pm SD (n=3 independent experiments) Source data are provided as a Source Data file.



Supplementary Fig. 14 Fluorescence imaging of small red thrombus sections incubated with free C-6, C6/N-BD NAs, C6/B-BD NAs or C6/T-BD NAs under 808 nm laser irradiation (2 W/cm², 15 min). scale bar = 1 μ m. Experiment was repeated three times independently with similar results.



Supplementary Fig. 15 Pharmacokinetic profiles of DiR Sol, B-BD NAs, T-BD NAs, and N-BD NAs after intravenous administration at an equivalent DiR dose of 5 mg/kg, n=5. Data are presented as mean ± SD (n=5 rats) Source data are provided as a Source Data file.



Supplementary Fig. 16 The coagulation indicators of activated partial thromboplastin time (APTT) in FeCl₃induced rat carotid arterial thrombosis model after different treatments (DiR equivalent dose 5 mg/kg, n=3). Data are presented as mean \pm SD. Source data are provided as a Source Data file.



Supplementary Fig. 17 H&E staining sections of the major organs (heart, liver, spleen, lung, and kidney) of rats after treatment with T-BD NAs for 14 days in FeCl₃-induced rat carotid arterial thrombosis model under laser irradiation (2.0 W/cm², 15 min), scale bar = 100 μ m. The Sham rats were used as control. Experiment was repeated three times independently with similar results.



Supplementary Fig. 18 H&E staining sections of carotid artery in rats after various treatment: Sham group, Embolism group, and T-BD NAs + L group (808 nm laser irradiation, 2.0 W/cm², 15 min), scale bar = 100 μ m. Experiment was repeated three times independently with similar results.



Supplementary Fig. 19 In vivo photothermal imaging of T-BD NAs in the embolized tails.



Supplementary Fig. 20 The coagulation indicators of activated partial thromboplastin time (APTT) after different treatments in mouse tail thrombosis model (DiR equivalent dose 5 mg/kg, n=3). Data are presented as mean \pm SD (n=5 rats) Source data are provided as a Source Data file.



Supplementary Fig. 21 Brain fluorescence imaging of T-BD NAs and DiR Sol in the MCAO model rats and health rats (Sham) after intravenous injection at an equivalent DiR dose of 5 mg/kg.



Supplementary Fig. 22 H&E staining sections of the brain tissues in the Sham group and T-BD NAs + L group (2 W/cm², 15 min), scale bar = 100 μ m. Experiment was repeated three times independently with similar results.

Supplementary Fig. 23 (a) Hemolysis results and quantitative analysis of hemoglobin content in the supernatants without laser irradiation. (b) Hemolysis images and quantitative analysis of hemoglobin content in the supernatants with the laser irradiation (2 W/cm², 5 min). Data are presented as mean \pm SD (n=3 independent experiments) Source data are provided as a Source Data file.

Supplementary Fig. 24 Cell viability of HUVEC after incubation with various concentrations of (a) DiR Sol, (b) BNN6 Sol, (c) BD Sol, (d) B-BD NAs, (e) T-BD NAs or (f) N-BD NAs for 48 h with/without laser irradiation (2 W/cm², 5 min). Data are presented as mean \pm SD (n=3 biologically independent cells) Source data are provided as a Source Data file.

Supplementary Fig. 25 Hepatorenal function parameters of the rats after different treatments (n=3). Data are presented as mean \pm SD. Source data are provided as a Source Data file.

Supplementary Fig. 26 H&E staining sections of the heart, liver, spleen, lung, and kidney in the MCAO rats after different treatments, scale bar = $100 \mu m$. Experiment was repeated three times independently with similar results.

Formulations (DiR/BNN6)	Size ^a (nm)	PDI ^b
10:1	137.7 ± 1.8	0.06 ± 0.04
8:1	138.8 ± 6.3	0.13 ± 0.03
5:1	135.7 ± 7.2	0.11 ± 0.01
3:1	128.3 ± 1.1	0.16 ± 0.05
1:1	91.3 ± 2.5	0.09 ± 0.01
1:3	76.1 ± 0.8	0.12 ± 0.01
1:5	77.9 ± 7.4	0.26 ± 0.01
1:8	176.4 ± 23.1	0.34 ± 0.02
1:10	168.7 ± 16.7	0.47 ± 0.14

Supplementary Tab. 1 Characterization of B-BD NAs at different molar ratios of DiR and BNN6.

^{a)} Mean diameters of B-BD NAs measured by DLS. ^{b)} Polydispersity index of B-BD NAs.

NAs Size ^a (nm)	Sizal (mm)	DDIp	7-4-3 (Drug loading rates ^c	
	PDI	Zeta [*] (mv)	DiR	BNN6	
B-BD NAs	76.1 ± 0.8	0.12 ± 0.01	18.33 ± 0.46	54.8%	45.2%
T-BD NAs	105.0 ± 9.2	0.11 ± 0.02	-7.65 ± 2.17	41.1%,	33.9%
N-BD NAs	118.7 ± 1.3	0.33 ± 0.02	-5.80 ± 1.31	45.4%	29.4%

Supplementary Tab. 2 Characterization of B-BD NAs, T-BD NAs and N-BD NAs.

^{a)} Mean diameters and Zeta potential of NAs measured by DLS. ^{b)} Polydispersity index of NAs. ^{c)}Drug loading rate of NAs.

Formulations	$C_{1h}^{a)}$	$AUC_{0-12 h}^{b)}$
DiR Sol	1.01 ± 0.21	9.720 ± 1.02
B-BD NAs	2.38 ± 0.64	21.06 ± 1.25
T-BD NAs	9.71 ± 1.80	75.23 ± 6.28
N-BD NAs	8.42 ± 0.67	63.01 ±1.57

Supplementary Tab. 3 Pharmacokinetic parameters of DiR Sol, B-BD NAs, T-BD NAs, and N-BD NAs (n=5).

^{a)} The plasma concentration at 1 h (nmol/mL). ^{b)} Area under the plasma concentration-time curve (nmol/mL*h).